UP!

ZIOP $0.87

ZIOP target price
0.87
0
0
ZIOPHARM Oncology, Inc.
Type
Public
Traded as NASDAQ: ZIOP
Industry Biotechnology
Headquarters Boston, Massachusetts
Key people
Laurence J. N. Cooper, M.D., Ph.D. (CEO)
Caesar J. Belbel (COO)
Sir Murray Brennan
Randal J. Kirk (Director)
Website ZIOPHARM.com

ZIOPHARM Oncology is a publicly held, clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that develops novel immunotherapies for the treatment of cancer.

In 2011, ZIOPHARM established a partnership with Intrexon Corporation to develop and commercialize DNA-based cancer drugs based on Intrexon's synthetic biology technology platform.

ZIOPHARM has two oncology therapeutics in clinical development, IL-12 DNA and CD-19-Sleeping Beauty Cells, and expects to initiate five additional CAR-T cell therapy clinical programs in 2015.


Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2021 2022-02-23 Future report Set alerts
Q3 2021 2021-11-08 -0.11 -0.11
Q2 2021 2021-08-09 -0.11 -0.11
Q1 2021 2021-05-06 -0.10 -0.10
Q4 2020 2021-02-25 0.00 0.00
Q3 2020 2020-11-05 -0.10 -0.10
Q2 2020 2020-08-06 -0.09 -0.09
Q1 2020 2020-05-07 -0.09 -0.09
Q4 2019 2020-03-02 -0.09 -0.09
Q3 2019 2019-11-07 -0.43 -0.43

Ratings

2016-07-01 Reiterated Rating Griffin Securities Buy $21.00
2016-06-08 Reiterated Rating Wells Fargo Sell
2016-06-08 Reiterated Rating Wells Fargo & Co. Sell
2016-06-07 Reiterated Rating Griffin Securities Buy $21.00
2016-06-02 Initiated Coverage Raymond James Market Perform
2016-06-02 Initiated Coverage Raymond James Financial Inc. Market Perform
2016-05-26 Reiterated Rating Griffin Securities Buy $21.00
2016-05-19 Reiterated Rating Wells Fargo Sell
2016-05-12 Reiterated Rating Wells Fargo Sell $6.50
2016-05-11 Boost Price Target Mizuho Neutral $6.00 to $7.00
2016-01-25 Boost Price Target Mizuho Hold to Neutral $6.00 to $10.00
2016-01-22 Reiterated Rating Wells Fargo Sell
2016-01-15 Reiterated Rating JPMorgan Chase & Co. Hold
2015-12-10 Reiterated Rating Griffin Securities Buy $21.00
2015-12-03 Initiated Coverage Wells Fargo Underperform
2015-11-05 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-09-29 Reiterated Rating JPMorgan Chase & Co. Hold
2015-09-17 Reiterated Rating Griffin Securities Buy $21.00
2015-08-14 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-06-22 Downgrade BMO Capital Markets Outperform to Market Perform $15.00 to $10.00
2015-06-10 Reiterated Rating Mizuho Neutral $14.00 to $10.00
2015-05-13 Initiated Coverage Guggenheim Neutral
2015-05-10 Reiterated Rating BMO Capital Markets Outperform $15.00
2015-03-30 Set Price Target Griffin Securities Buy $21.00
2015-03-10 Downgrade Mizuho Buy to Neutral $14.00
2015-03-02 Boost Price Target Mizuho Buy $11.00 to $14.00
2015-02-27 Reiterated Rating JPMorgan Chase & Co. Hold
2015-01-28 Set Price Target BMO Capital Markets Buy $15.00
2015-01-14 Reiterated Rating Griffin Securities Buy $12.00
2015-01-14 Upgrade BMO Capital Markets Underperform to Outperform $1.00 to $15.00
2014-03-19 Initiated Coverage Mizuho Buy $11.00
2014-03-04 Upgrade Piper Jaffray Neutral
2012-04-02 Reiterated Griffin Securities Buy $9 to $12
2011-12-15 Initiated Global Hunter Securities Buy $9
2011-11-22 Initiated Collins Stewart Buy $9
2011-02-08 Reiterated Dawson James Buy $6 to $8
2010-08-02 Initiated Dawson James Buy $6
2010-01-28 Initiated Rodman & Renshaw Mkt Outperform $8
2008-11-21 Reiterated Rodman & Renshaw Mkt Outperform $8 to $3
2007-10-11 Initiated Oppenheimer Buy $10
2016-07-01 Reiterated Rating Griffin Securities Buy $21.00
2016-06-08 Reiterated Rating Wells Fargo Sell
2016-06-08 Reiterated Rating Wells Fargo & Co. Sell
2016-06-07 Reiterated Rating Griffin Securities Buy $21.00
2016-06-02 Initiated Coverage Raymond James Market Perform

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In ZIOP 0 funds of 2213 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
ESSEX WOODLANDS HEALTH VENTURES FUND VI L P 2.35%  (2371642) LJPC / ZIOP /
Cooper Laurence James Neil Chief Executive Officer 1.38%  (1389396) ZIOP /
LEWIS JONATHAN CEO 0.74%  (744145) ZIOP /
CANNON JAMES ANTHONY 0.38%  (387365) ZIOP /
MCINERNEY TIMOTHY 0.37%  (372120) EMIS / TGTX / ZIOP /
WEISER MICHAEL 0.22%  (224282) CHTP / EMIS / IOVA / TGTX / ZIOP /
BAGLEY RICHARD E President, COO & Treasurer 0.21%  (211239) ZIOP /
BELBEL CAESAR J EVP, Chief Legal Officer & Sec 0.21%  (207434) ZIOP /
LEBEL FRANCOIS Executive Vice President R&D 0.20%  (200566) ZIOP /
Fowler Wyche 0.16%  (156446) BDN / ZIOP /
KIRK RANDAL J 0.14%  (139513) APHB / HALO / OGEN / SNGX / SYN / TBIO / TGEN / XON / ZIOP /
Youssoufian Hagop Executive VP, CMO 0.09%  (92721) BIND / PGNX / ZIOP /
Lafond Kevin G Vice Pres., Treasurer, & CAO 0.09%  (88534) ZIOP /
BRENNAN MURRAY 0.07%  (72620) ZIOP /
FRAGIN GARY S 0.07%  (67500) ZIOP /
MAUNEY DAVID M MD EVP and Chief Business Officer 0.06%  (58662) ZIOP /
ABERCROMBIE GEORGE B 0.02%  (25000) BCRX / OCRX / THRX / ZIOP /
Amello Jason Executive Vice President & CFO 0.02%  (22377) AKBA / OPXA / ZIOP /